Last month, Biopharm’s managing director, Andrew Sinclair, and Dr. Yuki Abe headed to Dublin, Ireland, for the Continuous Manufacturing in Biopharmaceuticals conference hosted by Informa Life Sciences. In conjunction with Jean-Francois Hamel from MIT, the Biopharm team led a pre-conference workshop entitled Implementing a Continuous
What’s happening in downstream processing? Welcome to the latest instalment of our continuous processing blog series. In Part 2 we considered the overall cost picture of the economics of continuous processing and touched upon the impact of perfusion versus fed batch – a theme we
Last month, Biopharm joined hundreds of exhibitors and thousands of visitors in attending Interphex Japan. The Tokyo-based tradeshow and conference covers the whole process of pharmaceuticals R&D and manufacturing. On the first day, Mark Bamforth, CEO of Gallus Pharmaceuticals, gave a keynote presentation on “The
Some biopharma companies have been running perfusion bioreactors in a continuous mode for several decades. The choice of whether to use continuous or not was dictated by the product, and little has been published on the economics of continuous perfusion processes. In today’s blog we
Over the next couple of blogs, we’d like to take a closer look at continuous processing, including the challenges associated with it, focusing on the cost drivers for perfusion versus fed batch, and the potential for continuous downstream processing. Continuous processing has increasingly been seen
In conjunction with today’s launch of BioSolve Process 5, we have developed a whitepaper that demonstrates the significant savings that can be achieved by biopharma innovators in monoclonal antibody manufacture. The study used BioSolve Process to evaluate three different development scenarios: Current stainless steel technology
